The neuromodulation company PRECISIS GmbH has appointed Karl Stoklosa as its new CEO. Stoklosa succeeds Angela Liedler, who is retiring. With his extensive international experience, Stoklosa will continue to drive the company’s strategic direction and strengthen expansion in the core markets in Europe and the USA.
Karl Stoklosa ©Precisis
The Heidelberg-based MedTech company Precisis GmbH, which specializes in neuromodulatory therapies, has appointed Karl Stoklosa as its new CEO, effective September 1, 2024. Stoklosa previously held various management positions at Abbott Laboratories, most recently as Director of Global Marketing for the CRM division. He succeeds Angela Liedler, who has successfully led the company since its founding years. Precisis was founded in 2009 and has established itself as an innovator with the EASEE brain pacemaker, a minimally invasive solution for the treatment of epilepsy. The company combines state-of-the-art technology with a deep understanding of the needs of patients and specialists. With a clear focus on the core markets in Europe and the USA, Precisis strives to improve the quality of life of people worldwide. With Stoklosa’s arrival, a new phase begins for the Heidelberg-based company, which has already established itself with the EASEE brain pacemaker.
German innovation company on course for expansion
“With Karl Stoklosa at the helm, we are sending a clear signal for the future of Precisis. He not only brings extensive international experience, but also the vision and determination needed to take our company to the next level,” emphasizes Dr. Felix Baader, Chairman of the Advisory Board of Precisis GmbH. “The MedTech industry is developing rapidly, and we are convinced that Stoklosa will continue to drive Precisis’ momentum and inspire our team.” This change in leadership marks the end of an era that was shaped by the outstanding work of Angela Liedler. Under her leadership, the innovative EASEE brain pacemaker was successfully brought to market – a milestone in the treatment of epilepsy. “Her entrepreneurial vision and commitment remain a role model for all of us,” adds Baader.
There is a lot to do: top manager becomes new CEO
Karl Stoklosa himself was full of enthusiasm for his new role: “It is a privilege to take over the management of Precisis at this exciting stage. Our goal is to improve the quality of life of millions of epilepsy patients worldwide – and to do so by using groundbreaking technologies. I am determined to further strengthen Precisis’ innovative power and set new standards in neuromodulation. Karl Stoklosa has made a name for himself as a top global manager who has consistently steered the road to success. His career is characterized by successful strategies and innovations, most recently as Director of Global Marketing at Abbott Laboratories, where he provided decisive impetus in the CRM division. He has an MBA from the renowned University of Chicago Booth School of Business.
Those: Precisis
